Alseres Pharmaceuticals Company Description
Unlike most people, the folks at Alseres Pharmaceuticals (formerly Boston Life Sciences) want to get on your nerves. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.
View the Comprehensive Company Description for Alseres Pharmaceuticals
The Company Description provides a historical perspective of Alseres Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Alseres Pharmaceuticals's evolution in the marketplace.
